Skip to Content
Merck
CN
  • Inhibition of PHLPP1/2 phosphatases rescues pancreatic β-cells in diabetes.

Inhibition of PHLPP1/2 phosphatases rescues pancreatic β-cells in diabetes.

Cell reports (2021-08-05)
Blaz Lupse, Karthika Annamalai, Hazem Ibrahim, Supreet Kaur, Shirin Geravandi, Bhavishya Sarma, Anasua Pal, Sushil Awal, Arundhati Joshi, Sahar Rafizadeh, Murali Krishna Madduri, Mona Khazaei, Huan Liu, Ting Yuan, Wei He, Kanaka Durga Devi Gorrepati, Zahra Azizi, Qi Qi, Keqiang Ye, Jose Oberholzer, Kathrin Maedler, Amin Ardestani
ABSTRACT

Pancreatic β-cell failure is the key pathogenic element of the complex metabolic deterioration in type 2 diabetes (T2D); its underlying pathomechanism is still elusive. Here, we identify pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 (PHLPP1/2) as phosphatases whose upregulation leads to β-cell failure in diabetes. PHLPP levels are highly elevated in metabolically stressed human and rodent diabetic β-cells. Sustained hyper-activation of mechanistic target of rapamycin complex 1 (mTORC1) is the primary mechanism of the PHLPP upregulation linking chronic metabolic stress to ultimate β-cell death. PHLPPs directly dephosphorylate and regulate activities of β-cell survival-dependent kinases AKT and MST1, constituting a regulatory triangle loop to control β-cell apoptosis. Genetic inhibition of PHLPPs markedly improves β-cell survival and function in experimental models of diabetes in vitro, in vivo, and in primary human T2D islets. Our study presents PHLPPs as targets for functional regenerative therapy of pancreatic β cells in diabetes.

MATERIALS
Product Number
Brand
Product Description

SAFC
Insulin, Human Recombinant, for research or for further manufacturing use, dry powder
Roche
In Situ Cell Death Detection Kit, TMR red, sufficient for ≤50 tests
Sigma-Aldrich
Insulin-Like Growth Factor-I, Human, Recombinant, E. coli, Animal-Free